Recurrent mutations in isocitrate dehydrogenase 2 (IDH2) occur in∼ 12% of patients with
acute myeloid leukemia (AML). Mutated IDH2 proteins neomorphically synthesize 2 …

Mutations in IDH2 genes (m IDH2) occur in approximately 12% of patients with acute
myeloid leukemia. Enasidenib is an oral, small-molecule inhibitor of mIDH2 proteins …

Growing evidence links abnormal epigenetic control to the development of hematological
malignancies. Accordingly, inhibition of epigenetic regulators is emerging as a promising …

Introduction: All-trans retinoic acid (ATRA, tretinoin) is the main drug used in the treatment of
acute promyelocytic leukemia (APL). Despite its impressive activity against APL, the same …

Advances in cancer therapy have increased the rate of survival of young cancer patients;
however, female lymphoma patients frequently face a temporary or permanent loss of fertility …

Interactions with cellular stress pathways are central to the life cycle of many latent viruses.
Here, we utilize adeno-associated virus (AAV) as a model to study these interactions, as …

Chronic cholestasis results in liver injury and eventually liver failure. Although
ursodeoxycholic acid (UDCA) showed limited benefits in primary biliary cirrhosis, there is an …

Telomeres are the capping ends of chromosomes that protect the loss of genetic material
and prevent chromosomal instability. In human tissue-specific stem/progenitor cells …

Background: This study evaluates the efficacy of combined chemotherapy for the
management of acute promyelocytic leukemia (APL). Method: Literature search was carried …

Acute promyelocytic leukemia (APL) is associated with PML-RARα oncogene, which is
treated using all-trans retinoic acid (ATRA)-based chemotherapy. However …